omecamtiv mecarbil
Sponsor Cytokinetics INC · listed as CYTK
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
omecamtiv mecarbil is a clinical-stage drug asset sponsored by Cytokinetics INC, listed as CYTK. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 2027 (month precision, medium confidence), tied to trial NCT06736574. The asset is in Phase 3 and currently recruiting, studied in Heart Failure.
Next catalyst
Event typeREADOUT
Expected date2027-09-30
As disclosedSep 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06736574
PhasePHASE3
StatusRECRUITING
Lead sponsorCytokinetics
Listed asCYTK
Condition(s)Heart Failure; Heart Failure With Reduced Ejection Fraction
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More CYTK catalysts